SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001447028-21-000072
Filing Date
2021-12-10
Accepted
2021-12-10 07:30:09
Documents
14
Period of Report
2021-12-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abus-20211209.htm   iXBRL 8-K 41415
2 EX-10.1 a2021-12x8xkxgenevantex.htm EX-10.1 46280
  Complete submission text file 0001447028-21-000072.txt   247978

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abus-20211209.xsd EX-101.SCH 2150
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abus-20211209_def.xml EX-101.DEF 4368
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abus-20211209_lab.xml EX-101.LAB 25876
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abus-20211209_pre.xml EX-101.PRE 14178
7 EXTRACTED XBRL INSTANCE DOCUMENT abus-20211209_htm.xml XML 12774
Mailing Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8 604-419-3200
Arbutus Biopharma Corp (Filer) CIK: 0001447028 (see all company filings)

IRS No.: 980597776 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34949 | Film No.: 211483649
SIC: 2834 Pharmaceutical Preparations